Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00005093 | Gemcitabine With or Without CI-994 in Treating Patients With Advanced Non-small Cell Lung Cancer | PHASE3 | COMPLETED | - | — | — | Dec 1, 1999 | May 1, 2001 | Aug 10, 2012 | 16 | United States, Canada |
| Name | Type | Description |
|---|---|---|
| gemcitabine hydrochloride | DRUG | - |
| tacedinaline | DRUG | - |
DISEASE CHARACTERISTICS: Histologically or cytologically confirmed recurrent, locally advanced, or metastatic, unresectable non-small cell lung cancer Failed or relapsed after one prior platinum containing regimen (cisplatin or carboplatin) as first line therapy Prior brain metastases allowed if res...